<DOC>
	<DOCNO>NCT00423670</DOCNO>
	<brief_summary>This open-label , randomized safety efficacy trial adult , treatment-naïve Chronic Hepatitis C ( CHC ) participant genotype 1 infection . The study conduct 2 part , compare standard-of-care PegIntron ( 1.5 μg/kg , weekly [ QW ] ) , plus ribavirin ( 800 1400 mg/day ) , 48 week five treatment paradigm contain boceprevir ( SCH 503034 ) 800 mg thrice day ( TID ) . The five treatment include boceprevir ( BOC ) plus standard-of-care 28 48 week , without 4-week lead-in PegIntron ( PEG ) ribavirin ( RBV ) , exploration PegIntron plus low-dose ribavirin ( 400 1000 mg/day ) plus boceprevir 48 week .</brief_summary>
	<brief_title>Safety Efficacy SCH 503034 Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 ( Study P03523 )</brief_title>
	<detailed_description>The study conduct 2 part . Part 1 study 5 arm use weight base ribavirin 800-1400 mg/day compare : - PegIntron ribavirin 48 week ( Arm 1 - Control ) - PegIntron , ribavirin , boceprevir 28 week ( Arm 2 ) - Lead-in PegIntron ribavirin 4 week follow PegIntron , ribavirin boceprevir 24 week ( Arm 3 ) - PegIntron , ribavirin boceprevir 48 week ( Arm 4 ) - Lead-in PegIntron ribavirin 4 week , follow PegIntron , ribavirin boceprevir 44 week ( Arm 5 ) Participants Arm 1 receive PegIntron ribavirin HCV positive 24 week treatment option receive boceprevir combination PegIntron ribavirin additional 24 week . All participant Arm 1 start boceprevir Week 24 form crossover arm ( Arm 8 ) . Part 2 study assess safety efficacy low dose ribavirin ( 400-1000 mg/day ) compare : - PegIntron , ribavirin ( 800-1400 mg/day ) boceprevir 48 week ( Arm 6 ) - PegIntron , low-dose ribavirin ( 400-1000 mg/day ) boceprevir 48 week ( Arm 7 ) Follow-up participant 72 week randomization .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Age 18 60 year ; Body weight 45 125 kg ; Documented chronic hepatitis C genotype 1 ; Liver biopsy histology consistent chronic hepatitis etiology chronic liver disease within 5 year Day 1 ; Participant participant 's partner ( ) must agree use acceptable method contraception 2 week prior Day 1 least 6 month last dose study medication ; Written inform consent . Include , limited , follow : Prior treatment hepatitis C ; Coinfection HIV hepatitis B virus ( HBsAg positive ) ; Evidence decompensated liver disease ; Diabetic hypertensive participant clinically significant ocular exam finding ; Preexisting psychiatric condition , include limit : Current moderate severe depression ; History depression associate following : Hospitalization depression ; Electroconvulsive therapy depression ; Depression result prolonged absence work and/or significant disruption daily function ; Suicidal homicidal ideation and/or attempt ; History severe psychiatric disorder ( include limit schizophrenia , psychosis , bipolar disorder , posttraumatic stress disorder mania ) ; Past history current use lithium ; Past history current use antipsychotic drug list condition . Substance abuse within protocol specify timeframes ; Preexisting medical condition could interfere participant 's participation completion study , include limited chronic pulmonary disease , cardiac dysfunction immunologicallymediated disease ; Active suspect malignancy history malignancy within past 5 year ; Participants pregnant nursing ; participant intend become pregnant study period . Male participant partner , intend become , pregnant study period . Treatment investigational drug participation clinical trial 30 day within Screening ; Hemoglobin &lt; 12 g/dL female &lt; 13 g/dL male ; Neutrophils &lt; 1500 mm^3 ; Blacks : &lt; 1200/mm^3 ; Platelets &lt; 100,000/mm^3 ; Other clinically significant laboratory test abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>